OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park Investment in new premises to create increase in cutting-edge genomic solutions and collaborative partnerships
OGT, a leading global provider of genomic research and diagnostic solutions, proudly announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand.
OGT, a leading global provider of genomic research and diagnostic solutions, proudly announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration.
“This is an exciting time of growth and development for us. As a leader in genomics research and diagnostics solutions, we are thrilled to celebrate the opening of our advanced facility in the heart of the Oxford Innovation Quarter,” said Adrian Smith, CEO of OGT. “From here, we can accelerate our next phase of product development and global expansion – providing our customers with greater access to leading-class products and tailored solutions backed by extensive collaboration and support.”
As part of the enhanced services at the new facility, customers will benefit from face-to-face support with OGT’s field application specialists within the new show lab. Here, the scientific team can give in-depth demonstrations for both NGS and FISH products, proving the capabilities of the company’s unique hybridisation technology. Designed in collaboration with recognised cancer experts, OGT’s SureSeq NGS panels offer unparalleled coverage completeness and uniformity, allowing accurate detection of key genetic aberrations in a wide range of haematological and solid tumour cancers. By collaborating closely with customers, OGT can help to progress the future of genetic-based medicine, providing comprehensive solutions tailored to the unique needs of its diverse customer base.
Investment Minister, Lord Dominic Johnson also commented on OGT’s expansion, “The UK is recognised as a world leader in life sciences and this multi-million-pound investment and expansion by OGT is another vote of confidence for our plan to grow the economy, increase prosperity and support jobs across the country. I am delighted that this larger, state-of-the-art site at the Oxford Technology Park will grow to bring together the best of investment and expertise, making the most of what the UK has to offer.”
For further information check www.ogt.com
